Andreas Hartkopf
Overview
Explore the profile of Andreas Hartkopf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich B, Kurbacher C, et al.
Eur J Cancer
. 2023 Dec;
198:113480.
PMID: 38154393
Background: In MONALEESA-2, addition of ribociclib to letrozole resulted in significantly longer progression-free survival (PFS) in postmenopausal women with HR+HER2- advanced breast cancer (ABC). RIBociclib for the treatment of advanCed...
12.
Hartkopf A, Janni W, Banys-Paluchowski M, Bidard F, Thomssen C
Breast Care (Basel)
. 2023 Dec;
18(6):493-496.
PMID: 38125919
No abstract available.
13.
Westphalen C, Krause B, Schuler M, Brucker S, Hartkopf A, Rasche L, et al.
Oncol Res Treat
. 2023 Sep;
46 Suppl 4:2-26.
PMID: 37748444
Die diesjährige Frühjahrstagung der DGHO (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V.) stand unter der Überschrift «Herausforderungen in der Onkologie - personalisierte Therapiesteuerung». Über drei Themenkomplexe hinweg wurden...
14.
Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C, et al.
J Exp Clin Cancer Res
. 2023 Aug;
42(1):210.
PMID: 37596623
Despite tremendous progress in deciphering breast cancer at the genomic level, the pronounced intra- and intertumoral heterogeneity remains a major obstacle to the advancement of novel and more effective treatment...
15.
Lukac S, Dayan D, Fink V, Leinert E, Hartkopf A, Veselinovic K, et al.
Arch Gynecol Obstet
. 2023 Jul;
308(6):1831-1844.
PMID: 37458761
Background: As the available information about breast cancer is growing every day, the decision-making process for the therapy is getting more complex. ChatGPT as a transformer-based language model possesses the...
16.
Dayan D, Ebner F, Janni W, Schochter F, Hartkopf A, Lorenz S, et al.
Arch Gynecol Obstet
. 2023 Jul;
309(3):1109-1110.
PMID: 37453941
No abstract available.
17.
Gluz O, Nitz U, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, et al.
JAMA Oncol
. 2023 May;
9(7):946-954.
PMID: 37166817
Importance: Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC). Despite some promising data on endocrine therapy (ET) combination with dual...
18.
Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, et al.
Eur J Cancer
. 2022 Dec;
179:48-55.
PMID: 36495689
Background: Sequencing of tumour tissue with comprehensive gene panels is increasingly used to guide treatment in precision oncology. Analysis of tumour-normal pairs allows in contrast to tumour-only assessment direct discrimination...
19.
Ruoff F, Kersten N, Anderle N, Jerbi S, Stahl A, Koch A, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139700
In cancer, the complex interplay between tumor cells and the tumor microenvironment results in the modulation of signaling processes. By assessing the expression of a multitude of proteins and protein...
20.
Anderle N, Koch A, Gierke B, Keller A, Staebler A, Hartkopf A, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740561
In light of the frequent development of therapeutic resistance in cancer treatment, there is a strong need for personalized model systems representing patient tumor heterogeneity, while enabling parallel drug testing...